IOVANCE BIOTHERAPEUTICS, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Iovance reported Q2 2026 product revenue of $99.3M (vs. $59.9M in Q2 2025), driven by U.S. Amtagvi sales of ~$91M (+40% vs. Q4 2025) and Proleukin revenue of ~$9M. Gross margin improved to 56%. The company is reviewing its FY2026 revenue guidance ($350M–$370M) based on strong demand and will update in Q3. FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas (undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma). Amtagvi now approved in three markets (U.S., Australia, Canada); UK resubmission under expedited review. Cash position was $304M as of June 30, 2026, expected to fund operations into H2 2028. Net loss for H1 2026 was $126.4M on revenue of $170.7M.
Why this rating
66% revenue growth and margin expansion are material for a $535M company; guidance review suggests upside. Still unprofitable but approaching inflection. Pipeline FDA designations and geographic expansion reduce risk materially.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.